B
BetaGlue
A loco-regional radio-therapy platform for tumors
About BetaGlue
BetaGlue Technologies is an innovative startup focused on revolutionizing cancer treatment through localized internal radiotherapy. The company has developed a cutting-edge technology that allows for the highly controlled administration of radionuclides—radioactive substances used in medical treatments—directly into tumor masses or surgical beds after tumor removal. This method ensures maximum treatment efficacy while minimizing unwanted side effects both locally and throughout the body.
BetaGlue Technologies primarily serves the healthcare sector, specifically targeting oncologists and medical institutions that treat solid tumors. The company operates in the global medical device market, offering a unique solution that has been cleared for use worldwide.
The business model of BetaGlue Technologies is centered around the development and commercialization of its proprietary radiotherapy platform. The company generates revenue by selling its specialized medical devices and related compounds to hospitals, clinics, and cancer treatment centers. Additionally, BetaGlue may engage in partnerships or licensing agreements with other medical technology firms to expand its market reach and application.
The core technology involves a new anti-tumoral compound based on Yttrium-90 (90Y) microspheres, which are embedded in a biocompatible matrix. This compound is delivered to the target area using a proprietary delivery system that ensures precise administration of the required dose of energy. This intra-operative method is designed to maximize treatment efficacy and improve patient safety.
BetaGlue Technologies is backed by a global team of industry professionals with a proven track record in bringing innovative medical solutions to market. Their expertise and commitment to advancing cancer treatment make BetaGlue a promising player in the field of localized internal radiotherapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 34.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Oncology, EIC, EIC Fund, Radiotherapy, Hard Tech, Horizon Europe, ogr torino, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2025 | $0 | — | EIC Fund | — |
| EARLY VC✓Equity / VC | Dec 2024 | $6.6M | $44M | Fondazione ENEA Tech | ↗ |
Growth signals
Latest recorded traffic for BetaGlue is 850 monthly website visits, down 15% over the last three months. BetaGlue's team declined 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BetaGlue in the Milan ecosystem
The BetaGlue office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A10 investors entered at this stage
Innogest Capital
Panakès Partners
NEVA SGR
LIFTT- RORomed
- PRProfequycapital
Fin Posillipo
EIC Fund
Giovanni Cerutti
Fondazione ENEA Tech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BetaGlue on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BetaGlue’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










